A peroxisome proliferator‐activated receptor gamma (<i>PPARG</i>) polymorphism is associated with zoledronic acid‐related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling

Martino, Maria Teresa Di; Arbitrio, Mariamena; Guzzi, Pietro Hiram; Leone, Emanuela; Baudi, Francesco; Piro, Eugenio; Prantera, T.; Cucinotto, Iole; Calimeri, Teresa; Rossi, Marco; Veltri, Pierangelo; Cannataro, Mario; Tagliaferri, Pierosandro; Tassone, Pierfrancesco

doi:10.1111/j.1365-2141.2011.08622.x

Cited by 70 publications

(42 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Di Martino et al [91 ] , studied 1,936 genetic variants of 225 genes in a case-control study of 19 patients with myeloma treated with zoledronic acid (9 with ONJ and 10 controls). Eight SNPs in four genes (PPARG, ABP1, CHST11 and CROT) were significantly associated with ONJ.…”

Section: Osteonecrosis Of the Jaw (Onj)mentioning

confidence: 99%

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

López-Delgado¹,

Riancho‐Zarrabeitia²,

Riancho³

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Section: Osteonecrosis Of the Jaw (Onj)mentioning

confidence: 99%

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

López-Delgado¹,

Riancho‐Zarrabeitia²,

Riancho³

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

“…This study represents the first attempt to investigate a candidate gene directly involved in BPs' mechanism of action. Katz and colleagues 23 recruited patients with multiple myeloma only, including 12 ONJ cases and 66 25 studied 1936 SNPs relevant to 225 genes associated with drug metabolism, disposition, and transport in 9 patients with multiple myeloma and ONJ treated with zoledronate and 10 matched controls. The investigators claimed that using a platform that interrogates only highly selective SNPs has the advantage of avoiding an extremely high number of comparisons, and therefore avoids the need for statistical corrections and large patient cohorts.…”

Section: Discovery Candidate Gene Studiesmentioning

confidence: 99%

“…In the past few years, several small studies have investigated the potential association of ONJ development with genetic factors. [21][22][23][24][25][26][27][28][29][30][31] This article provides a critical and comprehensive review of the available evidence regarding pharmacogenetics of ONJ.…”

Section: Key Pointsmentioning

confidence: 99%

“…Therefore, it has been suggested that candidate gene design is more suitable for replication studies. 51 A total of 9 candidate gene studies on ONJ were published between 2010 and 2013, [22][23][24][25][26][27][29][30][31] including both replication and discovery gene studies.…”

Section: Candidate Gene Studies On Osteonecrosis Of the Jawmentioning

confidence: 99%

“…[23][24][25][26]29,31 These studies analyzed the separate and combined effects of variants located in several genes, which had been chosen because they may relate to BP metabolism and/or ONJ pathogenesis (eg, bone turnover). Most of them screened only a small number of variants and had small cohorts, and are therefore susceptible to methodological limitations such as inadequate power.…”

Section: Discovery Candidate Gene Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw

Fung

Nicoletti

Shen

et al. 2015

Oral and Maxillofacial Surgery Clinics of North America

View full text Add to dashboard Cite

Osteonecrosis of the jaws (ONJ) is a potentially severe disorder that develops in a subgroup of individuals who have used bisphosphonate (BP) medications. Several clinical risk factors have been associated with the risk of ONJ development, but evidence is limited and in most instances ONJ remains an unpredictable adverse drug reaction. Interindividual genetic variability can contribute to explaining ONJ development in a subset of BP users and the discovery of relevant associated gene variants could lead to the identification of individuals at higher risk. No genetic variant has been found to be robustly associated with susceptibility to ONJ.

show abstract

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Arbitrio

Scionti

Altomare

et al. 2019

Clin Pharma and Therapeutics

Self Cite

View full text Add to dashboard Cite

Taxane‐related peripheral neuropathy (TrPN) is a dose‐limiting toxicity with important interindividual variability. Genetic polymorphisms in absorption, distribution, metabolism, and excretion (ADME) genes may account for variability in drug efficacy and/or toxicity. By the use of Affymetrix drug‐metabolizing enzyme and transporter microarray platform, in a retrospective case‐control study, the correlation between ADME polymorphic variants and grades ≥ 2−3‐TrPN was investigated. In a breast cancer (BC) training set, five single‐nucleotide polymorphisms in NR1I3 and UDP‐glucuronosyltransferase (UGT)2B7 genes were correlated to grades ≥ 2−3‐TrPN protection. By receiver operating characteristic curves, the grades ≥ 2−3‐TrPN‐related candidate biomarkers in an independent series of 54 patients with BC (17 cases and 37 controls) were validated. NR1I3 was correlated to paclitaxel‐TrPN and UGT2B7 to docetaxel‐TrPN. Moreover, a genetic signature of prognostic relevance for BC outcome was found. Our findings might have potential relevance for personalized management of patients with BC for prevention of treatment failure in ultrametabolizer genetic variants.

show abstract

A peroxisome proliferator‐activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid‐related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling

Cited by 70 publications

References 9 publications

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Contact Info

Product

Resources

About